kabutan

ZERIA PHARMA, Ordinary Profit Forecast for First Half Revised Downward by 47%

Fri Oct 31, 2025 4:00 pm JST Revision

4559 ZERIA PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Guidance Update Report

ZERIA PHARMACEUTICAL CO.,LTD. <4559> [TSE Prime] announced a performance revision after the market closed on October 31st (16:00). The consolidated ordinary profit forecast for the cumulative second quarter of the fiscal year ending March 2026 (April to September) has decreased 47.0%, from the previous forecast of 5.00 billion yen to 2.65 billion yen (compared to 7.94 billion yen in the same period of the previous year), leading to an increase in the profit decline rate from 37.1% to 66.7%.

Furthermore, the full-year ordinary profit forecast remains unchanged from the estimate of 12.0 billion yen(compared to 12.8 billion yen in the previous period).

Kabutan News

Guidance Update

First Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Prev 43,000 5,000 5,000 4,000 90.8 24 May 8, 2025 J-GAAP
Apr - Sep, 2025 New 39,960 3,640 2,650 1,730 39.3 24 Oct 31, 2025 J-GAAP
Revision Rate -7.1% -27.2% -47.0% -56.8% -56.7%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 42,422 6,459 7,949 6,061 137.5 23 Nov 6, 2024 J-GAAP
Apr - Sep, 2025 Guidance 39,960 3,640 2,650 1,730 39.3 24 Oct 31, 2025 J-GAAP
YoY -5.8% -43.6% -66.7% -71.5% -71.5%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 75,725 9,621 8,513 7,731 175.4 44 May 9, 2024 J-GAAP
Mar, 2025 87,311 12,197 12,840 9,936 225.4 47 May 8, 2025 J-GAAP
Mar, 2026 Guidance 90,000 12,000 12,000 9,500 215.5 48 May 8, 2025 J-GAAP
YoY +3.1% -1.6% -6.5% -4.4% -4.4%

Related Articles